Advantages of gadolinium based ultrasmall nanoparticles vs molecular gadolinium chelates for radiotherapy guided by MRI for glioma treatment

Cancer Nanotechnology

Volumn 5, Issue 1, 2014, Pages 1-14

  Le Duc, Géraldine ^a   Roux, Stéphane ^b   Paruta Tuarez, Amandine ^c   Dufort, Sandrine ^d   Brauer, Elke ^a   Marais, Arthur ^c   Truillet, Charles ^c   Sancey, Lucie ^c   Perriat, Pascal ^e   Lux, François ^c   Tillement, Olivier ^c  

^a EUROPEAN SYNCHROTRON RADIATION FACILITY   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c UNIVERSITÉ LYON 1   (France)

^d Nano H SAS   (France)

^e CNRS   (France)

Author keywords

3 10 : Gadolinium; DOTA; MRI; Nanoparticles; Radiosensitization

Indexed keywords

GADOLINIUM; GADOLINIUM CHELATE; GADOTERATE MEGLUMINE; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOMIC EMISSION SPECTROMETRY; CANCER SURVIVAL; CONTROLLED STUDY; GLIOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIGHT SCATTERING; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOSENSITIZATION; RAT; RELAXATION TIME; ZETA POTENTIAL;

EID: 84925680521     PISSN: 18686958     EISSN: 18686966     Source Type: Journal    
DOI: 10.1186/s12645-014-0004-8     Document Type: Article

References (36)

1. Stasiuk GJ, Long NJ (2013) The ubiquitous DOTA and its derivatives: the impact of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraaccetic acid on biomedical imaging. Chem Commun 49:2732–2746
2. Sherry AD, Caravan P, Lenkinski RE (2009) Primer on gadolinium chemistry. Magn Reson Med 30:1240–1248
3. Thomsen HS (2006) Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol 16:2619–2621
4. 111In-labeled cyclic RGD peptides: tetrameric not tetravalent. Bioconj Chem 21:969–978
5. Hong H, Yang Y, Zhang Y, Engle JW, Barnhart TE, Nickles RJ, Leigh BR, Cai W (2011) Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging 38:1335–1343
6. Moreau M, Raguin O, J–M V, Collin B, Bernhard C, Tizon X, Boschetti F, Duchamp O, Brunotte F, Denat F (2012) DOTAGA-Trastuzumab. A new antibody conjugate targeting HER2/ Neu Antigen for diagnostic purposes. Bioconj Chem 23:1181–1188
7. Zhou Z, Wu X, Kresak A, Griswold M, Zheng-Rong L (2013) Peptide targeted tripod macrocyclic Gd(III) chelates for cancer molecular MRI. Biomaterials 34:7683–7693
8. Rockey WM, Huang L, Kloepping KC, Baumhover NJ, Giangrande PH, Schultz MK (2011) Synthesis and radiolabelling of chelator-RNA aptamer bioconjugates with copper-64 for targeted molecular imaging. Bioorg Med Chem 19:4080–4090
9. Pagel MD (2011) The hope and hype of multimodality imaging contrast agents. Nanomedicine 6:945–948
10. 3+-based MRI contrast agents by conjugation with hydrophobic fluorescent dyes. Bioconj Chem 22:2227–2236
11. Hall MA, Kwon S, Robinson H, Lachance P-A, Azhdarinia A, Ranganathan R, Price RE, Chan W, Sevick-Muraca EM (2012) Imaging prostate cancer lymph node metastases with a multimodality contrast agent. Prostate 72:129–146
12. Frullano L, Catana C, Benner T, Sherry AD, Caravan P (2010) Bimodal MR-PET agent for quantitative pH imaging. Angew Chem Int Ed 49:2382–2384
13. Alric C, Taleb J, Le Duc G, Mandon C, Billotey C, Le Meur-Herland A, Brochard T, Vocanson F, Janier M, Perriat P, Roux S, Tillement O (2008) Gadolinium chelate coated gold nanoparticles as contrast agents for both X-ray computed tomography and magnetic resonance imaging. J Am Chem Soc 130:5908–5915
14. 64Cu-labeled magnetic nanoparticles for multimodal imaging. Bioconj Chem 19:1496–1504
15. Lux J, Chan M, Elst LV, Schopf E, Mahmoud E, Laurent S, Almutairi A (2013) Metal chelating crosslinkers form nanogels with high chelation stability. J Mater Chem B Mater Biol Med 46:6359–6364
16. Terreno E, Delli CD, Viale A, Aime S (2010) Challenges for molecular magnetic resonance imaging. Chem Rev 110:3019–3042
17. 1 contrast. Nat Nanotechnol 5:815–821
18. Maeda H (2010) Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjugate Chem 21:797–802
19. Petropoulos L, Seunders JK (2011) MRI and ultrasound guided treatment on a patient. US Patent 20110160566 A1
20. Pradhan AK, Naha SN, Montenegro M, Yu Y, Zhang HL, Sur C, Mrozik M, Pitzer RM (2009) Resonant X-ray enhancement of the auger effect in high-Z atoms, molecules, and nanoparticles: potential biomedical applications. J Phys Chem A 113:12356–12363
21. Hainfeld JF, Slatkin DN, Smilowitz HM (2004) The use of gold nanoparticles to enhance radiotherapy in mice. Phys Med Biol 49:N309–N315
22. Butterworth KT, McMahon SJ, Currel FJ, Prise KM (2012) Physical basis and biological mechanisms of gold nanoparticles radiosensitization. Nanoscale 4:4830–4838
23. Jain S, Coulter JA, Hounsell AR, Butterworth KT, McMahon SJ, Hyland WB, Muir MF, Dickson GR, Prise KM, Currel FJ, O’Sullivan JM, Hirst DG (2011) Cell-specific radiosensitization by gold nanoparticles at megavoltage radiation energies. Int J Radiat Oncol Biol Phys 79:531–539
24. Young SW, Qing F, Harriman A, Sessler JL, Dow WC, Mody TD, Hemmi GW, Hao YP, Miller RA (1996) Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc Natl Acad Sci U S A 93:6610–6615, Erratum in: Proc. Natl. Acad. Sci. U. S. A., 1999, 96:2569
25. Dehnad H, Kal HB, Stam T, Gademan IS, van Moorselaar RJ, van der Sanden BP (2003) Response to motexafin gadolinium and ionizing radiation of experimental rat prostate and lung tumors. Int J Radiat Oncol Biol Phys 57:787–793
26. Francis D, Richards GM, Forouzannia A, Mehta MP, Khuntia D (2009) Motexafin gadolinium: a novel radiosensitizer for brain tumors. Expert Opin Pharmacother 10:2171–2180
27. Le Duc G, Miladi I, Alric C, Mowat P, Bräuer-Krisch E, Bouchet A, Khalil E, Billotey C, Janier M, Lux F, Perriat P, Roux S, Tillement O (2011) Towards an image-guided microbeam radiation therapy using gadolinium-based nanoparticles. ACS Nano 5:9566–9574
28. Lux F, Mignot A, Mowat P, Louis C, Dufort S, Bernhard C, Denat F, Boschetti F, Brunet C, Antoine R, Dugourd P, Laurent S, Vander EL, Muller R, Sancey L, Josserand V, Coll J-L, Stupar V, Barbier E, Rémy C, Broisat A, Ghezzi C, Le Duc G, Roux S, Perriat P, Tillement O (2011) Ultrasmall rigid platforms as multimodal probes for medical applications. Angew Chem Int Ed 51:12299–13303
29. Mignot A, Truillet C, Lux F, Sancey L, Louis C, Denat F, Boschetti F, Bocher L, Gloter A, Stephan O, Antoine R, Dugourd P, Luneau D, Novitchi G, Figueiredo LC, De Morais PC, Bonneviot L, Albela B, Ribot F, Van Lokeren L, Dechamps-Olivier I, Chuburu F, Lemercier G, Villiers C, Marche PN, Le Duc G, Roux S, Tillement O, Perriat P (2013) A top-down synthesis route to ultrasmall multifunctionnal Gd-based nanoparticles for theranostic applications. Chem Eur J 19:6122–6136
30. Eisenwiener KP, Powell P, Maecke HR (2000) A convenient synthesis of novel bifunctionnal prochelators for coupling to bioactive peptides for radiometal labelling. Bioorg Med Chem Lett 10:2133–2135
31. Bernhard C, Moreau M, Lhenry D, Goze C, Boschetti F, Rousselin Y, Brunotte F, Denat F (2012) DOTAGA-anhydride: a valuable building block for the preparation of DOTA-like chelating agents. Chem Eur J 18:7834–7841
32. Bridot J-L, Faure A–C, Laurent S, Rivière C, Billotey C, Hiba B, Janier M, Josserand V, Coll J–L, Vander Elst L, Muller R, Roux S, Perriat P, Tillement O (2007) Hybrid gadolinium oxide nanoparticles: multimodal contrast agents for in vivo imaging. J Am Chem Soc 129:5076–5084
33. Bouchet A, Bidart M, Miladi I, Le Clec’h C, Serduc R, Coutton C, Regnard P, Khalil E, Dufort S, Lemasson B, Laissue J, Pelletier L, Le Duc G Characterization of the 9L gliosarcoma implanted in the Fisher rat: an orthotopic model for a grade IV brain tumor. Tumor Biol doi:10.1001/s13277-014-1783-6
34. Truillet C, Lux F, Tillement O, Dugourd P, Antoine R (2013) Coupling of HPLC with electrospray ionization mass spectrometry for studying the aging of ultrasmall multifunctional gadolinium-based nanoparticles. Anal Chem 85:10440–10447
35. Attenberger UI, Runge VM, Morelli JN, Williams J, Jackson CB, Mickaely HJ (2010) Evaluation of gadobutrol, a macrocyclic, nonionic gadolinium chelate in a brain glioma model: comparison with gadoterate meglumine and gadopentate dimeglumine at 1.5T, combined with an assessment of field strength dependence, specifically 1.5 versus 3T. J Magn Reson Imaging 31:549–555
36. 3 integrins. Bioconjugate Chem 24:1584–1597